JP2025131756A5 - - Google Patents
Info
- Publication number
- JP2025131756A5 JP2025131756A5 JP2025094518A JP2025094518A JP2025131756A5 JP 2025131756 A5 JP2025131756 A5 JP 2025131756A5 JP 2025094518 A JP2025094518 A JP 2025094518A JP 2025094518 A JP2025094518 A JP 2025094518A JP 2025131756 A5 JP2025131756 A5 JP 2025131756A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical formulation
- liquid pharmaceutical
- stable liquid
- concentration
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962821661P | 2019-03-21 | 2019-03-21 | |
| US62/821,661 | 2019-03-21 | ||
| PCT/US2020/023795 WO2020191270A1 (en) | 2019-03-21 | 2020-03-20 | Stabilized formulations containing anti-il-33 antibodies |
| JP2021556435A JP7695887B2 (ja) | 2019-03-21 | 2020-03-20 | 抗ｉｌ－３３抗体を含有する安定化製剤 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021556435A Division JP7695887B2 (ja) | 2019-03-21 | 2020-03-20 | 抗ｉｌ－３３抗体を含有する安定化製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025131756A JP2025131756A (ja) | 2025-09-09 |
| JP2025131756A5 true JP2025131756A5 (https=) | 2026-01-26 |
Family
ID=70228884
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021556435A Active JP7695887B2 (ja) | 2019-03-21 | 2020-03-20 | 抗ｉｌ－３３抗体を含有する安定化製剤 |
| JP2025094518A Pending JP2025131756A (ja) | 2019-03-21 | 2025-06-06 | 抗ｉｌ－３３抗体を含有する安定化製剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021556435A Active JP7695887B2 (ja) | 2019-03-21 | 2020-03-20 | 抗ｉｌ－３３抗体を含有する安定化製剤 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11596690B2 (https=) |
| EP (1) | EP3941522A1 (https=) |
| JP (2) | JP7695887B2 (https=) |
| KR (1) | KR20210141592A (https=) |
| CN (3) | CN119700966A (https=) |
| AU (1) | AU2020241882A1 (https=) |
| BR (1) | BR112021018727A2 (https=) |
| CA (1) | CA3133995A1 (https=) |
| CL (1) | CL2021002440A1 (https=) |
| CO (1) | CO2021011648A2 (https=) |
| EA (1) | EA202192568A1 (https=) |
| IL (2) | IL286024B2 (https=) |
| MA (1) | MA55362A (https=) |
| MX (1) | MX2021011137A (https=) |
| PH (1) | PH12021552092A1 (https=) |
| SA (1) | SA521430229B1 (https=) |
| SG (1) | SG11202109822XA (https=) |
| TW (2) | TW202519263A (https=) |
| WO (1) | WO2020191270A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120241997A (zh) | 2019-02-18 | 2025-07-04 | 伊莱利利公司 | 治疗性抗体制剂 |
| JP7804590B2 (ja) * | 2020-05-11 | 2026-01-22 | メディミューン リミテッド | 抗ｉｌ－３３抗体の処方物 |
| CN113603775B (zh) | 2021-09-03 | 2022-05-20 | 江苏荃信生物医药股份有限公司 | 抗人白介素-33单克隆抗体及其应用 |
| WO2023077685A1 (zh) * | 2021-11-04 | 2023-05-11 | 江苏荃信生物医药股份有限公司 | 包含抗人白介素-33单克隆抗体的浓缩溶液的制备方法及液体制剂 |
| CN113842457B (zh) * | 2021-11-04 | 2022-05-20 | 江苏荃信生物医药股份有限公司 | 包含抗人白介素-33单克隆抗体的液体制剂 |
| WO2026067832A1 (zh) * | 2024-09-30 | 2026-04-02 | 深圳市小分子新药创新中心有限公司 | 抗il-33单域抗体及其衍生物 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0747045B2 (ja) | 1986-10-15 | 1995-05-24 | 株式会社大協精工 | 積層した注射器用滑栓 |
| JP3100727B2 (ja) | 1992-01-23 | 2000-10-23 | 株式会社大協精工 | 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品 |
| JP3172057B2 (ja) | 1995-04-05 | 2001-06-04 | 株式会社大協精工 | ラミネートゴム栓 |
| JP3512349B2 (ja) | 1999-01-29 | 2004-03-29 | 株式会社大協精工 | 柱状ゴム要素の成形型 |
| ATE414151T1 (de) * | 2000-03-03 | 2008-11-15 | Cambridge Antibody Tech | Antikörper gegen eotaxin und deren verwendung |
| JP2002209975A (ja) | 2001-01-19 | 2002-07-30 | Daikyo Seiko Ltd | 医薬バイアル用ラミネートゴム栓 |
| NZ549040A (en) | 2004-02-17 | 2009-07-31 | Schering Corp | Use for interleukin-33 (IL33) and the IL-33 receptor complex |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| GB0600351D0 (en) * | 2006-01-10 | 2006-02-15 | Weston Terence E | Safe hypodermic needle |
| US8119771B2 (en) | 2007-04-26 | 2012-02-21 | The Provost, Fellow and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth, Near Dublin | Products for altering IL-33 activity and methods thereof |
| WO2008144610A1 (en) | 2007-05-18 | 2008-11-27 | Medimmune, Llc | Il-33 in inflammatory disease |
| EP2475388B1 (en) | 2009-09-10 | 2017-11-08 | Merck Sharp & Dohme Corp. | Use of il-33 antagonists to treat fibrotic disease |
| NZ609557A (en) * | 2010-10-06 | 2014-12-24 | Regeneron Pharma | Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies |
| WO2013059524A2 (en) * | 2011-10-18 | 2013-04-25 | Emory University | Antibodies directed against influenza |
| US8883979B2 (en) * | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
| PT3889181T (pt) * | 2012-09-07 | 2024-05-29 | Regeneron Pharma | Um anticorpo antagonista de il-4r para utilização no tratamento da dermatite atópica por administração |
| JO3532B1 (ar) | 2013-03-13 | 2020-07-05 | Regeneron Pharma | الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها |
| EA201890891A1 (ru) | 2015-10-06 | 2018-09-28 | Ридженерон Фармасьютикалз, Инк. | Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение |
| TWI784988B (zh) | 2016-12-01 | 2022-12-01 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
| MY197202A (en) * | 2017-03-16 | 2023-05-31 | Lg Chemical Ltd | A liquid formulation of anti-tnf alpha antibody |
| US20240124889A1 (en) * | 2019-05-07 | 2024-04-18 | Voyager Therapeutics, Inc. | Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation |
| CN112851814B (zh) * | 2020-03-17 | 2023-07-07 | 西安宇繁生物科技有限责任公司 | 一种靶向bcma的全人源单链抗体及其制备方法与应用 |
| EP4255451A4 (en) * | 2020-12-03 | 2025-01-01 | The Board Of Regents Of The University Of Texas System | Methods for identifying lilrb-blocking antibodies |
| TW202237639A (zh) * | 2020-12-09 | 2022-10-01 | 日商武田藥品工業股份有限公司 | 鳥苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法 |
-
2020
- 2020-03-19 TW TW113138408A patent/TW202519263A/zh unknown
- 2020-03-19 TW TW109109133A patent/TWI861073B/zh active
- 2020-03-20 BR BR112021018727A patent/BR112021018727A2/pt unknown
- 2020-03-20 WO PCT/US2020/023795 patent/WO2020191270A1/en not_active Ceased
- 2020-03-20 EA EA202192568A patent/EA202192568A1/ru unknown
- 2020-03-20 MX MX2021011137A patent/MX2021011137A/es unknown
- 2020-03-20 PH PH1/2021/552092A patent/PH12021552092A1/en unknown
- 2020-03-20 IL IL286024A patent/IL286024B2/en unknown
- 2020-03-20 KR KR1020217033469A patent/KR20210141592A/ko active Pending
- 2020-03-20 CN CN202411908169.7A patent/CN119700966A/zh active Pending
- 2020-03-20 JP JP2021556435A patent/JP7695887B2/ja active Active
- 2020-03-20 AU AU2020241882A patent/AU2020241882A1/en active Pending
- 2020-03-20 SG SG11202109822X patent/SG11202109822XA/en unknown
- 2020-03-20 IL IL317899A patent/IL317899A/en unknown
- 2020-03-20 MA MA055362A patent/MA55362A/fr unknown
- 2020-03-20 EP EP20718107.4A patent/EP3941522A1/en active Pending
- 2020-03-20 CN CN202411908014.3A patent/CN119700965A/zh active Pending
- 2020-03-20 CA CA3133995A patent/CA3133995A1/en active Pending
- 2020-03-20 US US16/825,007 patent/US11596690B2/en active Active
- 2020-03-20 CN CN202080021576.XA patent/CN113573733B/zh active Active
-
2021
- 2021-09-02 CO CONC2021/0011648A patent/CO2021011648A2/es unknown
- 2021-09-05 SA SA521430229A patent/SA521430229B1/ar unknown
- 2021-09-20 CL CL2021002440A patent/CL2021002440A1/es unknown
-
2023
- 2023-02-03 US US18/105,772 patent/US20230346929A1/en active Pending
-
2025
- 2025-06-06 JP JP2025094518A patent/JP2025131756A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025131756A5 (https=) | ||
| US20230047111A1 (en) | Pharmaceutical formulations of tnf-alpha antibodies | |
| JP5946448B2 (ja) | 持続型ヒト成長ホルモン結合体液状製剤 | |
| TWI806150B (zh) | 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物 | |
| JP2019509311A5 (https=) | ||
| CA2794929A1 (en) | Concentrated protein formulations and uses thereof | |
| HRP20241131T1 (hr) | Visokokoncentrirane formulacije inhibitornih antitijela masp-2 niske viskoznosti, pribori i metode | |
| BR112012017979B1 (pt) | Formulações líquidas para conjugado de g-csf de ação prolongada | |
| JP2013500947A5 (https=) | ||
| JP2013517309A (ja) | タンパク質用の医薬製剤 | |
| WO2009007272A1 (en) | Novel formulation | |
| CA2944330A1 (en) | Liquid pharmaceutical composition of adalimumab | |
| JP2022526292A5 (https=) | ||
| WO2021067775A1 (en) | Anto-connexin antibody formulations | |
| WO2020081408A1 (en) | Formulations of anti-rsv antibodies and methods of use thereof | |
| CA2888442A1 (en) | Stable pharmaceutical composition of peginterferon alpha-2b | |
| WO2008029908A1 (fr) | Préparation pharmaceutique lyophilisée stable comprenant un anticorps | |
| JP7587507B2 (ja) | 製剤 | |
| WO2009079837A1 (en) | A pharmaceutical formulation containing recombinant human serum albumin-interferon alpha fusion protein | |
| CN116249552A (zh) | 一种液体制剂及其应用 | |
| CN100542611C (zh) | 含有重组人血清白蛋白-干扰素α融合蛋白的注射用水剂 | |
| CN115518151B (zh) | 一种人类免疫缺陷病毒中和抗体制剂及其用途 | |
| JP2024532736A5 (https=) | ||
| RU2016152691A (ru) | Водная фармацевтическая композиция рекомбинантного моноклонального антитела к ФНОα | |
| RU2024121592A (ru) | Лиофилизированная композиция, содержащая слитый белок, включающий α-галактозидазу А |